SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

25 marketing jobs

Genentech logo
5 months ago

Senior Customer Marketing Manager - Patient

Genentech

Daly City, CA (Hybrid)Full time$162K/yr – $301K/yr
Genentech logo
5 months ago

Senior Therapeutic Area Marketer

Genentech

San Francisco, CA (Hybrid)Full time$162K/yr – $301K/yr
Genentech logo
6 months ago

Senior Customer Marketing Manager, Patient

Genentech

San Francisco, CA (Hybrid)Full time$162K/yr – $301K/yr
Genentech logo
6 months ago

Customer Marketing Director - Patient, Gastroenterology

Genentech

Indianapolis, IN (On-site)Full time$190K/yr – $352K/yr
Genentech logo
6 months ago

Customer Marketing Director - Access, Gastroenterology

Genentech

Indianapolis, IN (On-site)Full time$190K/yr – $352K/yr
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

25 jobs
Genentech logo

Senior Customer Marketing Manager - Patient

Genentech

Daly City, CA (Hybrid)

$162K/yr - $301K/yrIn-houseFull-timeSenior level5+ years exp.
5 months ago
Genentech logo

Senior Therapeutic Area Marketer

Genentech

San Francisco, CA (Hybrid)

$162K/yr - $301K/yrIn-houseFull-timeSenior level5+ years exp.
5 months ago
Genentech logo

Senior Customer Marketing Manager, Patient

Genentech

San Francisco, CA (Hybrid)

$162K/yr - $301K/yrIn-houseFull-timeSenior level5+ years exp.
6 months ago
Genentech logo

Customer Marketing Director - Patient, Gastroenterology

Genentech

Indianapolis, IN (On-site)

$190K/yr - $352K/yrIn-houseFull-timeDirector/executive8+ years exp.
6 months ago
Genentech logo

Customer Marketing Director - Access, Gastroenterology

Genentech

Indianapolis, IN (On-site)

$190K/yr - $352K/yrIn-houseFull-timeDirector/executive8+ years exp.
6 months ago
Previous12
Genentech logo
Genentech

Senior Customer Marketing Manager - Patient

Daly City, CA (Hybrid)

$162K/yr – $301K/yrSenior Level5+ years expFull time

Posted 5 months ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Drive end-to-end, omnichannel customer marketing strategy and campaigns with cross-functional collaboration and agency management.

  • Must-have: 5 years of marketing experience with 3 years in commercial roles
  • Standout: Leads cross-functional alignment with Legal, Regulatory, and agencies to pull through compliant tactics

Job Description

Responsibilities

  • Supports the development and execution of the customer strategy and the end-to-end integrated customer experience
  • Supports tailored and actionable omnichannel customer engagement, leveraging appropriate customer insights including customer journeys, personas, market/competitor insights and other data needed, collaborating closely with the Customer Marketer Lead
  • Responsible for planning and executing seamless, well-integrated marketing campaigns that include tailored omnichannel engagement plans across multiple marketing platforms and channels
  • Oversees the design and creation of core materials with Agencies of Record (AoR), websites, claims, components, tailoring original content to specific customer segments and personas while monitoring timelines and content handoffs
  • Self-authors derivative tactics for marketing campaigns leveraging existing and emerging technologies/capabilities, with a greater emphasis on new derivatives and incorporates post-Promotional Review Committee (PRC) edits and adjustments
  • Supports field deployment through communication, training and feedback loops
  • Hypothesizes and conducts experiments for creative content iteration, for the purpose of driving excellence in content creation and deployment
  • Partners with agencies and internal stakeholders, including Legal and Regulatory, to ensure development, approval, and pull-through of compliant and effective promotional tactics
  • Accountable for high quality, compliant execution across all marketing platforms and relevant customer types (e.g. patients, providers, organized customers)
  • Defines measurement plan and measures marketing performance through leading, lagging, and customer satisfaction indicators to optimize campaigns and drive customer and business outcomes

Requirements

  • Bachelor's degree
  • 2 years of marketing experience or 1 year of marketing experience and an MBA
  • 5 years minimum work experience, with 3 years of commercial experience (e.g., market access, marketing, sales or customer insights)

Preferred

  • MBA or other related graduate level degree preferred
  • Marketing experience in relevant industries
  • Experience working in an omnichannel (including field) marketing
  • Experience in the managed care, Pharmaceutical or Biotech industry/pharmaceutical or biotech customer engagement
  • Experience in creating customer strategies, plans and tactics that have strengthened market positioning and driven high-value customer and business outcomes
  • Experience leading/managing Agency partners including developing agency briefs and creating content derivatives
  • Contributed to integrated customer experiences across audiences and channels including multicultural and inclusive marketing tactics.

Benefits

  • Genentech is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat any and all employees and applicants on the basis of merit, qualifications, and competence. The company's policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of Protected Veteran status, individuals with disabilities status, and consistent with all federal, state, or local laws.
  • If you have a disability and need an accommodation in relation to the online application process, please contact us by completing this form Accommodations for Applicants .
Genentech logo

Genentech

4.1 Glassdoor

About GenentechWe're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683)Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines:1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages.2. Don’t mention any medicines by name — ours or anyone else’s.Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments.3. This isn’t the place to report or discuss side effects.This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch.4. Don’t pitch your product or service.Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Founded in 1976
South San Francisco, California, USA
18K employees (668 in marketing)
www.gene.com
80% recommend to a friend
79% CEO approval

Salaries

Posted range

$162K/yr – $301K/yr

Taken straight from the job posting.

See all Genentech salaries

Marketing Team

Marketing Team Size
537 (3% of company)
Median Career Experience
19 years
Median Tenure
11.1 years
Marketing Roles Posted (Last 30 Days)
6

People

HR / Recruitment

Andrew Kaufman
Andrew Kaufman
Global Talent Marketing Partner
At the company for 4 years 4 months

Marketing Leadership

Hayley Evans
Hayley Evans
Sr. Operations Manager, Operations & Administration – Chief Marketing Office (CMO)
At the company for 9 months
Zoë Harris Lazarre PhD MPH
Zoë Harris Lazarre PhD MPH
Chief Marketing Officer
At the company for 16 years
Ozgun (Oz) Demir
Ozgun (Oz) Demir
CHIEF MARKETING OFFICE | Head of Digital Marketing & Lymphoma Marketing Lead
At the company for 3 years 9 months
Srikar Bongoni
Srikar Bongoni
Sr. Director | Head of Performance Marketing
At the company for 6 years 10 months

Funding

Total Funding
$330.2M
Last Raise
$330.2M
Series A, 18 days ago

Funding History

  • Feb 2026
    Series A • $330.2M

Traffic Signals

Monthly Visitors
364.3K
Monthly Google Ads Budget
$3.6K
Traffic Source Mix
Search
44.2%
Direct
39.1%
Referral
9.3%
Social
6.3%
Paid
1%

Headcount Trend

Current headcount: ~18.1K

Recent News

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Nov 9, 2025 • Yahoo Finance
Roche's Genentech cuts 118 jobs at HQ in year's third round of layoffs
Oct 30, 2025 • FirstWord Pharma
Genentech says goodbye to 118 employees in 3rd HQ layoff round of the year
Oct 29, 2025 • Fierce Biotech
Genentech’s Latest Layoffs Bring Total to Nearly 350 This Year
Oct 29, 2025 • BioSpace
Genentech to lay off more than 100 employees
Oct 28, 2025 • KRON4
Ventus and Genentech partner for small-molecule medicine discovery
Oct 22, 2025 • Pharmaceutical Technology
Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus' ReSOLVE® Platform
Oct 21, 2025 • Business Wire
Genentech preps for flu season with DTC program offering discounted Xofluza
Oct 16, 2025 • Fierce Pharma
Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers
Oct 16, 2025 • CNBC
Scott St. Germain, U.S. Army Veteran and Vice President at Genentech, Joins Dream Foundation Board
Oct 15, 2025 • The Santa Barbara Independent
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
Oct 12, 2025 • Yahoo Finance
Biogen told to pay $124M in patent dispute with Genentech
Oct 6, 2025 • Fierce Pharma
Biogen owes Genentech $88 million in MS drug dispute, US judge says
Oct 1, 2025 • Reuters
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Revolution Medicines, Inc.
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
Sep 29, 2025 • BioSpace
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
Sep 26, 2025 • Spherix Global Insights
Roche points to U.S. plans after Trump pharma tariff announcement
Sep 26, 2025 • MarketScreener
Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
Sep 26, 2025 • Investing.com
Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
Sep 26, 2025 • MarketScreener
Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Sep 25, 2025 • Spherix Global Insights
Stanford U Spinout Pumpkinseed Pursues Chip-Based Peptide Sequencing, Immune Cell Analysis
Sep 25, 2025 • GenomeWeb
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
Sep 24, 2025 • Morningstar.com
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
Sep 24, 2025 • BioSpace
Genentech presents new Ocrevus, fenebrutinib data at ECTRIMS congress
Sep 24, 2025 • thefly.com
Starpharma inks license agreement with Genentech
Sep 23, 2025 • The Pharma Letter
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
Sep 23, 2025 • Yahoo Finance
In the clinic for Sept. 23, 2025
Sep 23, 2025 • BioWorld Financial Watch
Genentech to file for oral SERD approval on Phase III breast cancer win
Sep 22, 2025 • Clinical Trials Arena
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
Sep 22, 2025 • BioSpace
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
Sep 22, 2025 • BioSpace
Starpharma Announces a Collaboration and License Agreement with Genentech
Sep 22, 2025 • Starpharma
Genentech $569M deal lifts Starpharma stock 73%
Sep 22, 2025 • BioWorld Financial Watch
Starpharma enters collaboration, license agreement with Genentech
Sep 22, 2025 • thefly.com
Genentech announces evERA study meets both co-primary endpoints
Sep 22, 2025 • thefly.com
Genentech launches 'population health' unit led by former head of DEI effort
Sep 19, 2025 • Seattle TechFlash
Genentech names next marketing chief as Erica Taylor takes on new role at Roche
Sep 18, 2025 • Fierce Pharma
The Unsung Heroes: Why Healthcare Marketing Must Embrace...
Sep 16, 2025 • PharmiWeb
GLP-1s claim the longevity stage at ARDD
Sep 15, 2025 • Longevity.Technology - Latest News, Opinions, Analysis and Research
Reddit Highlights Opportunity for Healthcare Brands
Sep 11, 2025 • Social Media Today
Shannon Turley now part of Amgen Research’s bold new era
Sep 10, 2025 • Pharma Letter
Medical Affairs Summit 2025
Sep 10, 2025 • PharmiWeb
Genentech Named Official Supporter of AwareNow’s MS Channel, Recognized as a “Cause Champion”
Sep 9, 2025 • EIN Presswire
N.C. Community College System Reports Strong Year for Flagship NCEdge Customized Training Program
Sep 9, 2025 • PR Newswire
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Sep 8, 2025 • PharmiWeb
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
Sep 5, 2025 • BioSpace
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
Sep 5, 2025 • Business Wire
Genentech announces data from AVONELLE-X, SALWEEN studies of Vabysmo
Sep 5, 2025 • thefly.com
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
Sep 5, 2025 • Morningstar.com
New Data for Genentech’s Vabysmo Reinforce Its Efficacy,...
Sep 5, 2025 • PharmiWeb
Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline
Sep 3, 2025 • FierceBiotech
OMass Therapeutics enters deal with Genentech for IBD candidate
Sep 3, 2025 • Pharma Letter
Roche's Genentech pens $420M deal for Omass' preclinical IBD program
Sep 2, 2025 • Fierce Biotech
Curis to Present at Upcoming Healthcare Conferences in September
Sep 2, 2025 • PR Newswire
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
Sep 2, 2025 • OMass Therapeutics
Omas therapeutics enters exclusive collab & license agreement with Genentech
Sep 2, 2025 • MarketScreener
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
Sep 2, 2025 • Business Wire
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
Sep 2, 2025 • PharmiWeb
Roche Makes Preclinical IBD Play in $420M+ OMass Pact
Sep 2, 2025 • BioSpace
OMass attracts $420m Roche wager on IBD programme
Sep 2, 2025 • pharmaphorum
Blood Cancer Awareness Month: What biotech holds in store
Sep 1, 2025 • Labiotech.eu
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
Aug 30, 2025 • Morningstar.com
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
Aug 30, 2025 • PharmiWeb
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
Aug 30, 2025 • Business Wire
Genentech break ground on $700m East Coast facility for manufacturing metabolic medicines
Aug 29, 2025 • BioProcess International
Roche begins building $700M obesity drug manufacturing facility in N.C.
Aug 28, 2025 • FiercePharma
The Role of RWD in Revolutionizing Clinical Trial Design
Aug 27, 2025 • MedCity News
Genentech begins construction of new manufacturing facility
Aug 26, 2025 • Pharmaceutical Technology
Genentech breaks ground on $700M facility in Holly Springs
Aug 26, 2025 • BioBuzz
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
Aug 26, 2025 • BioSpace
Roche's Genentech Unit Breaks Ground on US Manufacturing Site for Metabolic Medicines
Aug 26, 2025 • MarketScreener
Roche: begins to build plant in North Carolina
Aug 26, 2025 • MarketScreener
Roche breaks ground on US manufacturing facility
Aug 26, 2025 • pharmaphorum
Governor Stein Celebrates Genentech Groundbreaking in Holly Springs
Aug 25, 2025 • NC Governor (.gov)
Biotech company Genentech breaks ground in Holly Springs
Aug 25, 2025 • WRAL.com
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
Aug 25, 2025 • Business Wire
Genentech breaks ground on $700M North Carolina facility
Aug 25, 2025 • FirstWord Pharma
Genentech breaks ground on Holly Spring factory
Aug 25, 2025 • Business North Carolina
Genentech Breaks Ground on Manufacturing Site in Holly Springs, NC
Aug 25, 2025 • Contract Pharma
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Aug 25, 2025 • F. Hoffmann-La Roche Ltd
Genentech initial investment in North Carolina is estimated at more than $700 million
Aug 25, 2025 • MarketScreener
Roche's Genentech Breaks Ground on North Carolina Manufacturing Site
Aug 25, 2025 • Morningstar.com
Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy Français
Aug 21, 2025 • Canada NewsWire
Natera Reports Improved Survival in Signatera-Positive Bladder Cancer Patients Receiving Tecentriq
Aug 19, 2025 • GenomeWeb
Biotech giant, Seattle firm end cancer drug deal once valued at $2 billion
Aug 19, 2025 • Seattle TechFlash
Roche pulls out of deal with Adaptive
Aug 19, 2025 • Pharma Letter
Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies
Aug 19, 2025 • BioSpace
Biotechnology & Pharmaceutical Services Outsourcing Market to Reach USD 182.94 Billion by 2035, Fact.MR Report
Aug 19, 2025 • EIN Presswire
Genentech scraps $2B deal with cell therapy biotech
Aug 18, 2025 • Fierce Biotech
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • BioSpace
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • Business Wire
How a Genentech cancer-fighting collaboration once valued at $2 billion ended with only $310 million paid out
Aug 18, 2025 • Seattle TechFlash
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • MarketScreener
Genentech Files Patent Suit Over Breast Cancer Biosimilar
Aug 15, 2025 • Law360
Using RWD, SDoH and Patient Mapping to Eliminate Blind Spots from the Patient Journey
Aug 13, 2025 • MedCity News
Neurointerventional Device Market is Forecasted to Reach USD 6.49 Billion By 2034, at an Impressive 7.43% CAGR
Aug 13, 2025 • EIN Presswire
Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech
Aug 12, 2025 • Research and Markets
Opinion: Antagonism to mRNA Technology Is Killing Our Best Shot At a Cure For Cancer
Aug 11, 2025 • BioSpace
Bicycle lays off 25% of workforce as Genentech rides away from R&D pact
Aug 8, 2025 • FierceBiotech
Bispecific Antibodies Market Size to Reach USD 220.82 Billion by 2032 | Oncology Drug Innovation and U.S. Market Leadership – SNS Insider
Aug 8, 2025 • SNS Insider pvt ltd

Links

www.gene.comLinkedInX (Twitter)Crunchbase